Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3181)	2/7/2012 9:31:30 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CRIS has continued the up-trend that started in December. I was up 6.21% on volume > 3x its ADV.<g> Its President and CEO, Dan Passeri, will be presenting at the 14th BIO CEO & Investor Conference at 10:00 a.m. EST, next Monday, in New York City. He is expected to provide an overview of Erivedge(vismodegib), a hedgehog pathway inhibitor, that CRIS developed in collaboration with Genentech, and is the first FDA-approved medicine for people with advanced forms of basal cell Ca. Mr. Passeri will also provide an overview of CRIS' other cancer programs including CUDC-101, CUDC-907 and Debio 0932 <g> bigcharts.marketwatch.com Bernard